159 related articles for article (PubMed ID: 8573451)
1. Bilateral prophylactic mastectomy: issues and concerns.
Stefanek ME
J Natl Cancer Inst Monogr; 1995; (17):37-42. PubMed ID: 8573451
[TBL] [Abstract][Full Text] [Related]
2. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
3. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Rebbeck TR; Friebel T; Lynch HT; Neuhausen SL; van 't Veer L; Garber JE; Evans GR; Narod SA; Isaacs C; Matloff E; Daly MB; Olopade OI; Weber BL
J Clin Oncol; 2004 Mar; 22(6):1055-62. PubMed ID: 14981104
[TBL] [Abstract][Full Text] [Related]
4. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic mastectomy and genetic testing: an update.
Houshmand SL; Campbell CT; Briggs SE; McFadden AW; Al-Tweigeri T
Oncol Nurs Forum; 2000; 27(10):1537-47; quiz 1548-9. PubMed ID: 11103373
[TBL] [Abstract][Full Text] [Related]
7. Physicians' attitudes towards mammography and prophylactic surgery for hereditary breast/ovarian cancer risk and subsequently published guidelines.
Julian-Reynier C; Eisinger F; Moatti JP; Sobol H
Eur J Hum Genet; 2000 Mar; 8(3):204-8. PubMed ID: 10780786
[TBL] [Abstract][Full Text] [Related]
8. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.
Grann VR; Jacobson JS; Whang W; Hershman D; Heitjan DF; Antman KH; Neugut AI
Cancer J Sci Am; 2000; 6(1):13-20. PubMed ID: 10696733
[TBL] [Abstract][Full Text] [Related]
9. Acceptance for preventive genetic testing and prophylactic surgery in women with a family history of breast and gynaecological cancers.
Ackermann S; Lux MP; Fasching PA; Strissl P; Renner SP; Poehls U; Bender HG; Beckmann MW
Eur J Cancer Prev; 2006 Dec; 15(6):474-9. PubMed ID: 17106324
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing.
Lerman C; Hughes C; Croyle RT; Main D; Durham C; Snyder C; Bonney A; Lynch JF; Narod SA; Lynch HT
Prev Med; 2000 Jul; 31(1):75-80. PubMed ID: 10896846
[TBL] [Abstract][Full Text] [Related]
11. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
[TBL] [Abstract][Full Text] [Related]
12. Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40.
Ardern-Jones A; Kenen R; Eeles R
Eur J Cancer Care (Engl); 2005 Jul; 14(3):272-81. PubMed ID: 15952973
[TBL] [Abstract][Full Text] [Related]
13. Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation.
Metcalfe KA; Foulkes WD; Kim-Sing C; Ainsworth P; Rosen B; Armel S; Poll A; Eisen A; Gilchrist D; Chudley A; Ghadirian P; Maugard C; Lemire EG; Sun P; Narod SA
Clin Genet; 2008 May; 73(5):474-9. PubMed ID: 18341607
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic bilateral mastectomy: patterns of practice.
Metcalfe KA; Goel V; Lickley L; Semple J; Narod SA
Cancer; 2002 Jul; 95(2):236-42. PubMed ID: 12124821
[TBL] [Abstract][Full Text] [Related]
15. [Genetic test and prophylactic treatment in breast cancer families].
Miyoshi Y; Noguchi S
Gan To Kagaku Ryoho; 2002 Apr; 29(4):512-22. PubMed ID: 11977534
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic mastectomy.
Zakaria S; Degnim AC
Surg Clin North Am; 2007 Apr; 87(2):317-31, viii. PubMed ID: 17498529
[TBL] [Abstract][Full Text] [Related]
17. Newly diagnosed breast cancer patients choose bilateral mastectomy over breast-conserving surgery when testing positive for a BRCA1/2 mutation.
Stolier AJ; Corsetti RL
Am Surg; 2005 Dec; 71(12):1031-3. PubMed ID: 16447474
[TBL] [Abstract][Full Text] [Related]
18. Predictors of and satisfaction with bilateral prophylactic mastectomy.
Stefanek ME; Helzlsouer KJ; Wilcox PM; Houn F
Prev Med; 1995 Jul; 24(4):412-9. PubMed ID: 7479633
[TBL] [Abstract][Full Text] [Related]
19. Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation.
Stolier AJ; Fuhrman GM; Mauterer L; Bolton JS; Superneau DW
Breast J; 2004; 10(6):475-80. PubMed ID: 15569201
[TBL] [Abstract][Full Text] [Related]
20. Screening for genetic risk of breast cancer.
Rosenthal TC; Puck SM
Am Fam Physician; 1999 Jan; 59(1):99-104, 106. PubMed ID: 9917577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]